| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFb113 |
| Uniprot No | Q30KQ7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-82aa |
| 氨基酸序列 | GPSV PQKKTREVAE RKRECQLVRG ACKPECNSWE YVYYYCNVNP CCAVWEYQKP IINKITSKLH QK |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFb113重组蛋白的虚构参考条目(基于常见研究方向模拟，非真实文献)：
1. **《重组人DEFb113蛋白的表达及其体外抗菌活性研究》**
- 作者：Zhang L, Wang Y, Chen H
- 摘要：通过原核表达系统成功获得高纯度重组DEFb113蛋白，验证其对革兰氏阴性菌(如大肠杆菌)和真菌(白色念珠菌)的抑菌活性，并发现其抗菌作用与破坏微生物膜结构相关。
2. **《DEFb113重组蛋白的结构表征及免疫调节功能》**
- 作者：Kim S, Tanaka M, Lee J
- 摘要：利用核磁共振技术解析DEFb113的β-折叠结构，揭示其通过TLR4/NF-κB通路激活巨噬细胞，增强IL-6和TNF-α分泌，提示其在先天免疫中的潜在作用。
3. **《DEFb113在皮肤感染模型中的重组表达与治疗应用》**
- 作者：Gupta R, Müller A
- 摘要：在银屑病样小鼠模型中，局部应用重组DEFb113显著降低金黄色葡萄球菌定植，同时抑制过度角质化，表明其兼具抗感染和修复屏障的双重功能。
4. **《DEFb113基因多态性对其重组蛋白功能的影响》**
- 作者：Fernández E, et al.
- 摘要：对比不同人群DEFb113基因SNP位点，发现rs12345突变导致重组蛋白电荷分布改变，显著降低其对HIV-1病毒颗粒的中和能力。
注：以上内容为模拟生成，实际文献需通过PubMed/Web of Science等平台检索确认。
**Background of DEFb113 Recombinant Protein**
DEFb113. a member of the β-defensin family, is a small cationic peptide encoded by the *DEFB113* gene in humans. Defensins are evolutionarily conserved components of innate immunity, broadly recognized for their antimicrobial and immunomodulatory activities. β-defensins, in particular, are secreted by epithelial cells and play critical roles in host defense by disrupting microbial membranes, recruiting immune cells, and modulating inflammatory responses. DEFb113 is primarily expressed in epithelial tissues, including the skin, respiratory tract, and urogenital tract, suggesting its importance in mucosal immunity.
Structurally, DEFb113 contains six conserved cysteine residues forming three disulfide bonds, a hallmark of β-defensins that stabilizes its fold and enhances resistance to proteolytic degradation. Its antimicrobial activity spans bacteria, fungi, and enveloped viruses, attributed to its ability to interact with negatively charged microbial membranes, causing permeabilization and cell death. Beyond direct pathogen neutralization, DEFb113 also acts as a chemokine, binding to receptors like CCR6 to recruit dendritic cells and memory T cells, thereby bridging innate and adaptive immunity.
Recombinant DEFb113 is produced via heterologous expression systems (e.g., *E. coli* or mammalian cell lines) for research and therapeutic exploration. Its recombinant form retains bioactive properties, enabling studies on its therapeutic potential in infections, chronic inflammation, or wound healing. Recent studies highlight its dual role in antimicrobial defense and tissue repair, with emerging interest in engineering DEFb113 derivatives to enhance stability or specificity. However, challenges such as off-target cytotoxicity and optimal delivery methods remain under investigation.
Overall, DEFb113 exemplifies the multifaceted nature of defensins, combining direct pathogen elimination with immune regulation, positioning it as a promising candidate for novel antimicrobial and immunotherapeutic strategies.
×
